James' World 2

Click the link below the picture

.

People with type 1 diabetes must constantly rely on insulin injections or pumps, usually for the rest of their life after diagnosis. The autoimmune disease destroys the cells that produce the hormone, which is crucial to keeping blood sugar in check. But now research suggests a new therapy could finally allow people with type 1 diabetes to make insulin on their own.

A 42-year-old man who has lived most of his life with type 1 diabetes has become the first human to receive a transplant of genetically modified insulin-producing cells that can slip past the immune system’s mistaken attacks. This marks the first pancreatic cell transplant in a human to sidestep the need for immunosuppressant drugs—and it might even lead to a future cure for the disease, researchers say.

“This is the most exciting moment of my scientific career,” says cell biologist Per-Ola Carlsson of Uppsala University in Sweden, who helped develop the procedure. The new treatment, he says, “opens the future possibility of treating not only diabetes but other autoimmune diseases.”

Scientists injected nearly 80 million genetically tweaked cells into the participant’s forearm muscle, and 12 weeks later the cells were still alive and producing insulin. The recipient did require additional insulin injections—but the injected cells showed no signs of rejection, which the researchers say is a major step forward. The results were reported this month in the New England Journal of Medicine.

About two million people in the U.S. live with type 1 diabetes, which typically requires an intensive regimen of insulin injections and blood sugar monitoring. If their blood sugar runs amok, people face severe risks, including heart attacks, nerve damage, vision problems, kidney disease, and more.

For decades, scientists have struggled to develop therapies that can successfully replenish beta cells—the specialized insulin-producing cells that are found in the pancreas. Newly added functional beta cells are usually quickly destroyed because a type 1 diabetic immune system flags them as invaders. A few past attempts successfully transplanted donor islets—clusters of pancreatic cells that included beta cells—but these always ultimately triggered an aggressive immune response. And such a response requires recipients to take lifelong immunosuppressive drugs, which come with serious side effects, such as increased risks of infections and cancer. For example, at a conference in June, Boston-based Vertex Pharmaceuticals announced that 10 out of 12 participants who were treated with a stem-cell-based infusion during a clinical trial no longer required insulin injections a year after the therapy. But they may continue to need to immunosuppressants.

In the new study, Carlsson and his team looked for ways to dodge the immune response. First, they broke down a deceased donor’s pancreatic islets into single cells. Using the common gene-editing technique CRISPR, the researchers inactivated in some of these cells two genes that control the expression of proteins called human leukocyte antigens, which direct the immune system to the foreign cells. Without those markers, the immune system can’t easily recognize and destroy the donor cells.

To further evade immune system detection, the team made some cells express higher levels of a gene that discourages attacks by the body’s natural killer cells and macrophages, two types of immune cells. Three months after the treatment, although the immune system attacked some cells in the graft, it left the cells that had the inactivated genes and overexpressed gene alone. Blood tests showed no measurable immune cell activation or antibody production in response to these cells.

Before the transplant, the participant had no measurable naturally produced insulin and was receiving daily doses of the hormone. But within four to 12 weeks following the transplant, his levels rose slightly on their own after meals—showing that the new beta cells were releasing some insulin in response to glucose. Four adverse events occurred, but none were serious or related to the modified cells.

The advance “is amazing,” says Laura Alonso, chief of the division of endocrinology, diabetes and metabolism at Weill Cornell Medicine, who was not involved in the new study. Unlike type 2 diabetes, in which people have poorly functioning beta cells, type 1 diabetes can destroy beta cells completely. Some people with type 1 diabetes may still have a small set of functional beta cells, but in more established cases, the immune system often whittles away all cells, Alonso says. For those established cases, she says, “cell-based therapy is where we need to go.”

.

.

.

Click the link below for the complete article:

.

__________________________________________

Click the link below the picture

.

Mosquitoes bite, suck your blood, and leave you with itchy bumps and possibly a horrible infection. Mosquito-borne pathogens include malaria, West Nile virus, Zika virus, Chikungunya virus, and dengue. No wonder so many of us want to learn how to kill mosquitoes for good.

While you might fantasize about living in a mosquito-free world, eradicating them would actually be disastrous for the environment. Adult mosquitoes are food for other insects, birds, and bats, while larval mosquitoes support aquatic ecosystems. The best we can hope for is to limit their ability to transmit disease, repel them, and kill them within the confines of our yards and homes.

Mosquito-killing products bring in the big bucks, so it should come as no surprise that there is a wealth of misinformation out there. Before you get sucked into buying a product that simply won’t work, get educated about what does and does not kill these blood-sucking pests.

.

Most people believe the only good mosquito is a dead mosquito. Doug4537 / Getty Images

.

.

Click the link below for the complete article:

.

__________________________________________

Click the link below the picture

.

California’s Democratic Governor Gavin Newsom has responded after a federal judge ruled Tuesday that the Trump administration broke the law by deploying National Guard troops to Southern California during immigration enforcement operations and related protests.

U.S. District Judge Charles Breyer in San Francisco stopped short of ordering the troops’ immediate removal but said his ruling would take effect Friday, September 12. Breyer is the younger brother of Stephen Breyer, who served as a Supreme Court justice from 1994 to 2022.

The ruling blocks the Trump administration from “deploying, ordering, instructing, training, or using the National Guard currently deployed in California, and any military troops heretofore deployed in California, to execute the laws, including but not limited to engaging in arrests, apprehensions, searches, seizures, security patrols, traffic control, crowd control, riot control, evidence collection, interrogation, or acting as informants.”

Newsom said in a statement, “Today, the court sided with democracy and the Constitution. No president is a king — not even Trump — and no president can trample a state’s power to protect its people. As the court today ruled, Trump is breaking the law by ‘creating a national police force with the President as its chief.’ That’s exactly what we’ve been warning about for months. There is no rampant lawlessness in California, and in fact, crime rates are higher in Republican-led states.”

Why It Matters

The ruling comes as Trump has discussed deploying the National Guard to various Democratic-led cities, including Chicago, Baltimore and New York, citing concerns about violent crime in the cities. However, crime statistics show that many Republican-run states and cities have equal, or higher, rates of crime.

Trump has already deployed the National Guard in Washington, D.C., in addition to placing the city’s police department under federal control.

“President Trump and Secretary Hegseth have stated their intention to call National Guard troops into federal service in other cities across the country—including Oakland and San Francisco, here in the Northern District of California—thus creating a national police force with the President as its chief,” Breyer wrote in his ruling.

What To Know

In June, Newsom and California Attorney General Rob Bonta filed an emergency request asking the court to block Trump and the Department of Defense from expanding the current mission of federalized Cal Guard personnel and Marines.

The governor’s office said the soldiers were ordered to “engage in unlawful civilian law enforcement activities in communities across the region.”

Roughly 4,000 National Guard soldiers and 700 Marines were deployed to Los Angeles in early June to deal with protests over immigration enforcement, despite objections from local and state officials.

What is the Posse Comitatus Act?

The Posse Comitatus Act is a law passed in 1878 that limits the use of federal military personnel. Breyer said the Trump administration violated the law in its deployment of the National Guard and Marines to Los Angeles.

“Because Defendants’ alleged violations of the Posse Comitatus Act include allegations that Task Force 51 troops have engaged in law enforcement—a domain traditionally within the state’s control—California has suffered an injury that gives it standing to challenge those violations,” Breyer wrote.

What People Are Saying

California Governor Gavin Newsom, in a statement, “Trump’s attempt to use federal troops as his personal police force is illegal, authoritarian, and must be stopped in every courtroom across this country.”

U.S. District Judge Charles Breyer, in a ruling, “Los Angeles was the first U.S. city where President Trump and Secretary Hegseth deployed troops, but not the last.”

What Happens Next

Breyer’s ruling is scheduled to go into effect on Friday, September 12, which could give the Trump administration time to appeal the ruling.

.

.

.

Click the link below for the complete article:

.

__________________________________________